Stalevo is an anti-parkinsonian dopaminergic combination medication that contains carbidopa, levodopa, and entacapone for the treatment of Parkinson's disease. It is marketed by Swiss-based Novartis Pharmaceuticals and manufactured by Finnish drugmaker Orion Corporation.
Read more about Stalevo: Indications, Dosing Forms, Mechanism of Action, Side Effects, Drug Interactions, Studies, See Also